Breast

Primary Site Histology
C500-C506, C508-C509 8000-8700, 8982-8983
C501-C506, C508-C509 8720-8790

Notes

8000-8700, 8720-8790 [except C500], 8982-8983 C500 Nipple C501 Central portion of breast C502 Upper-inner quadrant of breast C503 Lower-inner quadrant of breast C504 Upper-outer quadrant of breast C505 Lower-outer quadrant of breast C506 Axillary Tail of breast C508 Overlapping lesion of breast C509 Breast, NOS **Note 1:** The following sources were used in the development of this schema * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 48 *Breast*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** See the following schemas for the listed histologies * 8720-8790: *Melanoma Skin* (C500 only) * 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8940-8981, 8990, 9000-9016, 9030-9043, 9045-9138, 9141-9230, 9240-9580, 9582: *Soft Tissue Trunk and Extremities* * 8804-8806, 8930-8931, 8991, 9020, 9044, 9231, 9581: *Soft Tissue Rare* * 8935-8936: *GIST* * 8992: *Soft Tissue Other* * 9140: *Kaposi Sarcoma* * 9700-9701: *Mycosis Fungoides* **Note 3:** In addition to coding *EOD Primary Tumor, EOD Regional Nodes* and *EOD Mets*, the following data items are also needed to assign a stage group for Breast. * ER Summary * PR Summary * HER2 Summary * Oncotype Dx Recurrence Score

Data Items

Name Default Value Used in Derivation NAACCR Item Required By Metadata
Year of Diagnosis No NAACCR #390
dateOfDiagnosis 		None
Primary Site Yes NAACCR #400
primarySite 		None
Histology Yes NAACCR #522
histologicTypeIcdO3 		None
Behavior Yes NAACCR #523
behaviorCodeIcdO3 		None
Tumor Size Clinical No NAACCR #752
tumorSizeClinical 		None
Tumor Size Pathological No NAACCR #754
tumorSizePathologic 		None
Tumor Size Summary 999 Yes NAACCR #756
tumorSizeSummary 		None
Regional Nodes Positive 99 No NAACCR #820
regionalNodesPositive 		None
Regional Nodes Examined 99 No NAACCR #830
regionalNodesExamined 		None
Sentinel Lymph Nodes Positive 99 No NAACCR #835
sentinelLymphNodesPositive 		None
Sentinel Lymph Nodes Examined 99 No NAACCR #834
sentinelLymphNodesExamined 		None
LVI 9 No NAACCR #1182
lymphVascularInvasion 		None
RX Summ Surgery/Radiation Sequence No NAACCR #1380
rxSummSurgRadSeq 		None
RX Summ Systemic/Surgery Sequence No NAACCR #1639
rxSummSystemicSurSeq 		None
EOD Primary Tumor 999 Yes NAACCR #772
eodPrimaryTumor 		None
EOD Regional Nodes 999 Yes NAACCR #774
eodRegionalNodes 		None
EOD Mets 00 Yes NAACCR #776
eodMets 		None
SS2018 No NAACCR #764
summaryStage2018 		None
Grade Clinical 9 Yes NAACCR #3843
gradeClinical 		All SSDI
Grade Pathological 9 Yes NAACCR #3844
gradePathological 		All SSDI
Grade Post Therapy Clin (yc) Yes NAACCR #1068
gradePostTherapyClin 		All SSDI
Grade Post Therapy Path (yp) Yes NAACCR #3845
gradePostTherapy 		All SSDI
Lymph Nodes Positive Axillary Level I-II X8 Yes NAACCR #3882
lnPositiveAxillaryLevel1To2 		All SSDI
ER Summary 9 Yes NAACCR #3827
estrogenReceptorSummary 		All SSDI
ER Percent Positive XX8 No NAACCR #3826
estrogenReceptorPercntPosOrRange 		COC
SEER (RC)		 SSDI
ER Allred Score X8 No NAACCR #3828
estrogenReceptorTotalAllredScore 		COC
SEER (RC)		 SSDI
PR Summary 9 Yes NAACCR #3915
progesteroneRecepSummary 		All SSDI
PR Percent Positive XX8 No NAACCR #3914
progesteroneRecepPrcntPosOrRange 		COC
SEER (RC)		 SSDI
PR Allred Score X8 No NAACCR #3916
progesteroneRecepTotalAllredScor 		COC
SEER (RC)		 SSDI
HER2 Overall Summary 9 Yes NAACCR #3855
her2OverallSummary 		All SSDI
HER2 IHC Summary 8 No NAACCR #3850
her2IhcSummary 		CCCR/Canada 2018–2020
COC 2018–2020
SEER (RC) 2018–2020		 SSDI
HER2 ISH Summary 8 No NAACCR #3854
her2IshSummary 		CCCR/Canada 2018–2020
COC 2018–2020
SEER (RC) 2018–2020		 SSDI
HER2 ISH DP Ratio XX.8 No NAACCR #3852
her2IshDualProbeRatio 		COC 2018–2020
SEER (RC) 2018–2020		 SSDI
HER2 ISH DP Copy No XX.8 No NAACCR #3851
her2IshDualProbeCopyNumber 		COC 2018–2020
SEER (RC) 2018–2020		 SSDI
HER2 ISH SP Copy No XX.8 No NAACCR #3853
her2IshSingleProbeCopyNumber 		COC 2018–2020
SEER (RC) 2018–2020		 SSDI
Ki-67 (MIB-1) XXX.8 No NAACCR #3863
ki67 		COC
SEER (RC)		 SSDI
Oncotype DX Recur Score - Invasive XX9 Yes NAACCR #3904
oncotypeDxRecurrenceScoreInvasiv 		All SSDI
Oncotype Dx Risk Level - Invasive 8 No NAACCR #3906
oncotypeDxRiskLevelInvasive 		COC
SEER (RC)		 SSDI
Oncotype DX Recur Score - DCIS XX8 No NAACCR #3903
oncotypeDxRecurrenceScoreDcis 		COC
SEER (RC)		 SSDI
Oncotype Dx Risk Level - DCIS 8 No NAACCR #3905
oncotypeDxRiskLevelDcis 		COC
SEER (RC)		 SSDI
Multigene Signature Method 8 No NAACCR #3894
multigeneSignatureMethod 		COC
SEER		 SSDI
Multigene Signature Result X8 No NAACCR #3895
multigeneSignatureResults 		COC
SEER		 SSDI
Response Neoadjuv Therapy 8 No NAACCR #3922
responseToNeoadjuvantTherapy 		COC
SEER (RC)		 SSDI

Initial Context

Staging Methods

Expand All | Collapse All

Summary Stage 2018

Start

Additional Context
eod_2018_t = 90
eod_2018_m = 90
eod_2018_n = 90

Next Step

  2. EOD Primary Tumor
  3. ss2018_t

Next Step

  2. EOD Regional Nodes
  3. ss2018_n

Next Step

  2. EOD Mets
  3. ss2018_m

Next Step

  2. Summary Stage
  3. ss2018_derived

End

Outputs

Name Default Value Description NAACCR Item Metadata
Schema ID 00480 NAACCR #3800
schemaId 		None
Derived Version {{ctx_alg_version}} None None
Derived Summary Stage 2018 9 NAACCR #762
derivedSummaryStage2018 		None